Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPMT | P51580 | 2/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.46 |
| ▸ | PCNA | P12004 | 2/20 | 0.46 |
| ▸ | CES2 | O00748 | 2/20 | 0.44 |
| ▸ | CES1 | P23141 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4431892 | 0.87 | MAPT (0.48) | TPMTCA1CA2PARP10PCNA | |
| SCHEMBL6720943 | 0.86 | TPMT (0.50) | TPMTMEN1KMT2APARP10PCNA | |
| SCHEMBL6723673 | 0.86 | TPMT (0.54) | TPMTCA1CA2KDM4EMEN1 | |
| SCHEMBL237992 | 0.85 | CA1 (0.58) | TPMTCA1CA2KDM4EMEN1 | |
| SCHEMBL6135971 | 0.85 | PARP10 (0.45) | TPMTCA1CA2KDM4EPARP10 | |
| SCHEMBL6135849 | 0.85 | PARP10 (0.62) | TPMTCA1CA2KMT2APARP10 | |
| SCHEMBL4008454 | 0.85 | PCNA (0.61) | TPMTCA1CA2PARP10PCNA | |
| SCHEMBL6723577 | 0.84 | CA1 (0.54) | TPMTCA1CA2KDM4ERAB9A | |
| SCHEMBL6136046 | 0.83 | PLK1 (0.60) | CA1CA2PARP10PCNASMN1; SMN2 | |
| SCHEMBL7561681 | 0.83 | KMT2A (0.47) | KMT2APARP10PCNACES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115330-A1 | RADIOPAQUE MULTI-ARM POLYMERS FOR MEDICAL APPLICATIONS | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260041799-A1 | HYDROLYSIS-RESISTANT HYDROGELS AND METHODS OF TREATMENT USING SAME | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2026-02-12 | — | — | US | disclosed |
| US-20260014282-A1 | METHODS OF FORMING RADIOPAQUE PEPTIDES FOR USE IN MEDICAL HYDROGELS | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250249130-A1 | RADIOPAQUE POLYPEPTIDES FOR INJECTABLE COMPOSITIONS | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2025-08-07 | — | — | US | disclosed |
| EP-0954299-B1 | THYROXINE ANALOGUES HAVING NO SIGNIFICANT HORMONAL ACTIVITY FOR TREATING MALIGNANT TUMOURS | OCTAMER INC (US) | 2005-07-27 | — | — | EP | disclosed |
| EP-1024800-B1 | THYROXINE ANALOGUES HAVING NO SIGNIFICANT HORMONAL ACTIVITY TO TREAT MALIGNANT TUMORS | OCTAMER INC (US) | 2002-08-21 | — | — | EP | disclosed |
| US-6326402-B1 | AROMATIC ESTER COMPOUND | OCTAMER, INC. | 2001-12-04 | — | — | US | disclosed |
| US-6303621-B1 | ADMINISTERING DIIODO THYRONINE ANALOGUE HAVING NO SIGNIFICANT HORMONAL ACTIVITY AND A VINCA ALKALOID SELECTED FROM LEUROSINE, VINCALEUKOBLASTINE, VINBLASTINE, LEUROFORMINE, LEUROSIDINE, LEUROCRISTINE, VINCRISTINE, DEOXY VINBLASTINE | OCTAMER, INC. | 2001-10-16 | — | — | US | disclosed |
| EP-0954299-A4 | METHOD OF TREATING MALIGNANT TUMORS WITH THYROXINE ANALOGUES HAVING NO SIGNIFICANT HORMONAL ACTIVITY | OCTAMER INC (US) | 2000-09-06 | — | — | EP | disclosed |
| US-6017958-A | A THERAPEUTIC TREATMENT USING A METHYL ALKYLOXY- OR THIO-PHENYL BENZOATE, AS POTENT, SELECTIVE AND NON-TOXIC ANTI-TUMOR AGENTS FOR TREATING CANCER | OCTAMER, INC. (US) | 2000-01-25 | — | — | US | disclosed |
| EP-0954299-A1 | METHOD OF TREATING MALIGNANT TUMORS WITH THYROXINE ANALOGUES HAVING NO SIGNIFICANT HORMONAL ACTIVITY | Octamer, Inc. (US) | 1999-11-10 | — | — | EP | disclosed |
| US-5922775-A | ADMINISTERING A COMPOUND ABLE TO INHIBIT THE INITIAL VELOCITY OF MICROTUBULE PROTEIN ASSEMBLY IN VITRO; SUCH AS 1-(3,5-DIIODO-4-(4'-METHOXYPHENOXY)-PHENYL)-ETHANONE (DIPE) | OCTAMER, INC. (US) | 1999-07-13 | — | — | US | disclosed |
| US-5736576-A | ADMINISTERING METHYL 3,5-DIIODO-4-(4*-METHOXYPHENOXY)BENZOATE | OCTAMER, INC. (US) | 1998-04-07 | — | — | US | disclosed |
| WO-1997046228-A1 | METHOD OF TREATING MALIGNANT TUMORS WITH THYROXINE ANALOGUES HAVING NO SIGNIFICANT HORMONAL ACTIVITY | OCTAMER, INC. (US) | 1997-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115330-A1 | RADIOPAQUE MULTI-ARM POLYMERS FOR MEDICAL APPLICATIONS | KLK3, BRDT, BPHL | TPMT 4080/4885CA1 390/4885CA2 2180/4885 |
| US-20260014282-A1 | METHODS OF FORMING RADIOPAQUE PEPTIDES FOR USE IN MEDICAL HYDROGELS | IAPP, NPPA, ARG1 | TPMT 4779/4885CA1 226/4885CA2 609/4885 |
| US-20260041799-A1 | HYDROLYSIS-RESISTANT HYDROGELS AND METHODS OF TREATMENT USING SAME | PAM, CRYAA, COL1A1 | TPMT 3261/4885CA1 844/4885CA2 1401/4885 |
| US-20250249130-A1 | RADIOPAQUE POLYPEPTIDES FOR INJECTABLE COMPOSITIONS | IAPP, IGFBP6, NPPA | TPMT 4869/4885CA1 1262/4885CA2 3237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.